Press Conference Announcement
AASLD President’s Press Conference
Saturday, October 30, 2010 – 4:00-5:00 pm
Room 209, Hynes Convention Center
AASLD President’s Press Conference
Saturday, October 30, 2010 – 4:00-5:00 pm
Room 209, Hynes Convention Center
See Full Announcement
AASLD President Arun Sanyal, MD, will host a press conference on the first full day of presentations at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases.
Dr. Sanyal will highlight individual studies and themes from the 2047 abstracts to be presented at this year’s meeting from the leading researchers in the field. He has selected to review 16 abstracts in advance of their actual presentation in scientific sessions for the benefit of the media:
Hepatitis C
• Maintenance peginterferon (pegIFN) therapy to prevent hepatocellular carcinoma (HCC) in patients (pts) with advanced chronic hepatitis C (CHC): extended follow-up results from the HALT-C Trial
• Telaprevir in Combination with Peginterferon and Ribavirin in Genotype 1 HCV Treatment-Naïve Patients: Final Results of Phase 3 ADVANCE Study
• Telaprevir in Combination with Peginterferon Alfa2a and Ribavirin for 24 or 48 weeks in Treatment-Naïve Genotype 1 HCV Patients who Achieved an Extended Rapid Viral Response: Final Results of Phase 3 ILLUMINATE Study
• HCV RESPOND-2 Final Results: High Sustained Virologic Response Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin when Re-Treated with Boceprevir Plus PEGINTRON (Peginterferon alfa-2b)/Ribavirin
• Boceprevir (BOC) Combined with Peginterferon alfa-2b/Ribavirin (P/R) for Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype (G) 1: SPRINT-2 Final Results
• Impact of sustained virologic response to pegylated interferon/ribavirin on all-cause mortality by HCV genotype in a large real-world cohort: the US Department of Veterans Affairs’ experience
• An IL28B Genotype-Based Model for Personalized Prediction of Response to Pegylated-Interferon-Alfa and Ribavirin in the Treatment of Chronic Hepatitis C
Hepatitis B
• A Prospective and Open-Label Study for the Efficacy and Safety of Telbivudine(Ltd) in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus (HBV) to the Infants
Nonalcoholic Steatohepatitis
• Vitamin E, Metformin or Placebo for Treatment of Nonalcoholic Fatty Liver Disease in Children
• Mir34a: A potential link between nonalcoholic fatty liver disease (NAFLD) and diabetes mellitus
Drug-induced Liver Disease
• Investigation of hepatotoxicity and drug metabolism in a microscale model of the human liver
Acute Liver Failure
• A prospective randomized controlled multicenter study of extracorporeal liver support by Fractionated Plasma Separation and Adsorption (Prometheus®) in patients with acute-on-chronic liver failure (HELIOS study)
The Burden of Liver Disease
• Burden of cirrhosis and hepatic encephalopathy on patients and caregiver
Future of the Field
• The Use of Whole Organ Decellularization for the Bioengineering of a Human Vascularized Liver
• Engineering of a Transplantable Liver Graft
Dr. Sanyal is professor of medicine and chairman of the Division of Gastroenterology at Virginia Commonwealth University Medical Center in Richmond, Virginia.
After earning his undergraduate degrees from Patna University and Maulana Azad Medical College, both in India, Dr. Sanyal earned his doctor of medicine degree from the All India Institute of Medical Sciences in New Delhi. He completed a residency in internal medicine at the All India Institute of Medical Sciences, a residency in internal medicine at Texas Tech University Health Sciences Center in Amarillo, Texas, and a fellowship in gastroenterology and hepatology at VCU Medical Center, until being named Professor of Internal Medicine, Gastroenterology, Hepatology and Nutrition.
Dr. Sanyal has served as secretary of AASLD and as a member of various AASLD committees including the clinical research, NIH liaison, and program evaluation committees, and the international education sub-committee. He is also a member of the American College of Gastroenterology. Dr. Sanyal is the author of more than 100 articles in such publications as Gastroenterology, HEPATOLOGY, and the Journal of Infectious Diseases. His research interests include clinical studies in liver disease, hepatic neovascularization and genesis of TIPS stenosis, and the development of effective therapy for nonalcoholic steatohepatitis.
AASLD President Arun Sanyal, MD, will host a press conference on the first full day of presentations at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases.
Dr. Sanyal will highlight individual studies and themes from the 2047 abstracts to be presented at this year’s meeting from the leading researchers in the field. He has selected to review 16 abstracts in advance of their actual presentation in scientific sessions for the benefit of the media:
Hepatitis C
• Maintenance peginterferon (pegIFN) therapy to prevent hepatocellular carcinoma (HCC) in patients (pts) with advanced chronic hepatitis C (CHC): extended follow-up results from the HALT-C Trial
• Telaprevir in Combination with Peginterferon and Ribavirin in Genotype 1 HCV Treatment-Naïve Patients: Final Results of Phase 3 ADVANCE Study
• Telaprevir in Combination with Peginterferon Alfa2a and Ribavirin for 24 or 48 weeks in Treatment-Naïve Genotype 1 HCV Patients who Achieved an Extended Rapid Viral Response: Final Results of Phase 3 ILLUMINATE Study
• HCV RESPOND-2 Final Results: High Sustained Virologic Response Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin when Re-Treated with Boceprevir Plus PEGINTRON (Peginterferon alfa-2b)/Ribavirin
• Boceprevir (BOC) Combined with Peginterferon alfa-2b/Ribavirin (P/R) for Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype (G) 1: SPRINT-2 Final Results
• Impact of sustained virologic response to pegylated interferon/ribavirin on all-cause mortality by HCV genotype in a large real-world cohort: the US Department of Veterans Affairs’ experience
• An IL28B Genotype-Based Model for Personalized Prediction of Response to Pegylated-Interferon-Alfa and Ribavirin in the Treatment of Chronic Hepatitis C
Hepatitis B
• A Prospective and Open-Label Study for the Efficacy and Safety of Telbivudine(Ltd) in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus (HBV) to the Infants
Nonalcoholic Steatohepatitis
• Vitamin E, Metformin or Placebo for Treatment of Nonalcoholic Fatty Liver Disease in Children
• Mir34a: A potential link between nonalcoholic fatty liver disease (NAFLD) and diabetes mellitus
Drug-induced Liver Disease
• Investigation of hepatotoxicity and drug metabolism in a microscale model of the human liver
Acute Liver Failure
• A prospective randomized controlled multicenter study of extracorporeal liver support by Fractionated Plasma Separation and Adsorption (Prometheus®) in patients with acute-on-chronic liver failure (HELIOS study)
The Burden of Liver Disease
• Burden of cirrhosis and hepatic encephalopathy on patients and caregiver
Future of the Field
• The Use of Whole Organ Decellularization for the Bioengineering of a Human Vascularized Liver
• Engineering of a Transplantable Liver Graft
Dr. Sanyal is professor of medicine and chairman of the Division of Gastroenterology at Virginia Commonwealth University Medical Center in Richmond, Virginia.
After earning his undergraduate degrees from Patna University and Maulana Azad Medical College, both in India, Dr. Sanyal earned his doctor of medicine degree from the All India Institute of Medical Sciences in New Delhi. He completed a residency in internal medicine at the All India Institute of Medical Sciences, a residency in internal medicine at Texas Tech University Health Sciences Center in Amarillo, Texas, and a fellowship in gastroenterology and hepatology at VCU Medical Center, until being named Professor of Internal Medicine, Gastroenterology, Hepatology and Nutrition.
Dr. Sanyal has served as secretary of AASLD and as a member of various AASLD committees including the clinical research, NIH liaison, and program evaluation committees, and the international education sub-committee. He is also a member of the American College of Gastroenterology. Dr. Sanyal is the author of more than 100 articles in such publications as Gastroenterology, HEPATOLOGY, and the Journal of Infectious Diseases. His research interests include clinical studies in liver disease, hepatic neovascularization and genesis of TIPS stenosis, and the development of effective therapy for nonalcoholic steatohepatitis.
No comments:
Post a Comment